|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Improving Appropriate Utilization of Imaging in Prostate Cancer Patients: A Discussion on the RADAR Articles
|
E. David Crawford, MD
David Crawford joins Phillip Koo in a discussion on the Radiographic Assessments for Detection of Advanced Recurrence (RADAR) articles, which aimed to improve the appropriate utilization of imaging in prostate cancer patients. |
|
|
|
|
|
|
|
|
|
|
| Germline Testing for Prostate Cancer in 2023 — Unlocking the Codes
|
| Isla P. Garraway, MD, Ph.D. |
| Germline testing is indicated in individuals diagnosed with high risk and/or metastatic prostate cancer, and those with a significant family history of cancer or genetic alterations associated with cancer. The urologist has an important role in ensuring testing occurs by identifying candidates for testing and ensuring systems are in place to conduct testing, return of results, and appropriate referrals. |
|
|
|
|
|
| Follow-Up Lecture: Somatic Testing — What’s the Difference? Why Bother?
|
| Peter Carroll, MD, MPH
|
| Peter Carrol highlights the importance of somatic testing, which involves analyzing tumor samples for genetic mutations and alterations, in guiding treatment decisions for prostate cancer patients. Dr. Carrol emphasizes the differences between germline testing and somatic testing, and discusses the potential benefits and limitations of somatic testing in improving patient outcomes.
|
|
|
|
|
|
| How to Select Appropriate Candidates in Their 70’s for PSA Screening and Curative Treatment versus Observation Strategies
|
| Samuel L. Washington III, MD, MAS
|
| Samuel Washington discusses how to select appropriate candidates in their 70s for PSA screening and curative treatment versus observation strategies in prostate cancer. Dr. Washington highlights the benefits and risks of PSA screening and curative treatments for older men, as well as the importance of considering factors such as life expectancy, overall health status, and patient preferences when making treatment decisions.
|
|
|
|
|
|
|
|
|
|
|
| Prostate Cancer Guidelines — Where I See Progress and Help with My Practice |
| Stephen Boorjian, MD |
| In this presentation, Stephen Boorjian discusses the latest 2022 iteration of the joint AUA/ASTRO guidelines for clinically localized prostate cancer, focusing on how these most recent changes have helped him in his practice. |
|
|
|
|
|
| Next Generation Imaging Updates from the RADAR Group
|
| E. David Crawford, MD
|
| E David Crawford presents updates in next-generation imaging for prostate cancer from the RADAR group. This presentation highlights the latest advancements in imaging techniques, including multi-parametric magnetic resonance imaging (mpMRI) and PET-CT scans. Dr. Crawford highlights the potential benefits of these imaging technologies, including improved accuracy in detecting and staging prostate cancer, as well as their ability to guide treatment decisions.
|
|
|
|
|
|
| Oligometastatic Disease—Who/Why for Directed Therapy |
| R. Jeffrey Karnes, MD |
| Jeffrey Karnes discusses the role of metastasis-directed therapy for patients with oligometastatic, hormone-sensitive prostate cancer. Oligometastatic prostate cancer is often seen as an intermediary state in the progression from organ-confined to widely metastatic disease, although some have argued that the oligometastatic state is a non-intermediary, biologically/clinically unique state with distinct molecular signatures, not along the metastatic disease continuum. |
|
|
|
|
|
| First Update: Managing our Metastatic Hormone Sensitive Prostate Cancer Patients: Are We There Yet?
|
| Maha Hussain, MD, FACP, FASCO
|
| Maha Hussain reviews recent developments in the treatment of this condition, including the use of androgen deprivation therapy (ADT) in combination with chemotherapy and novel hormonal agents. Dr. Hussain also discusses the potential benefits and risks of these treatment approaches, as well as ongoing research aimed at identifying biomarkers and developing new therapies for metastatic prostate cancer.
|
|
|
|
|
|
| Second Update: Is Combination Therapy the New Standard of Care for Metastatic Castrate Resistant Prostate Cancer Patients?
|
| Fred Saad, MD, FRCS
|
| Fred Saad presents on use of combination therapy as a potential new standard of care for mCRPC patients. Dr. Saad discusses the results of recent clinical trials that have evaluated the efficacy of combining hormonal therapy with chemotherapy and/or novel targeted therapies for mCRPC and highlights the potential benefits of combination therapy, including improved survival and quality of life for patients, but also noted the potential side effects and challenges.
|
|
|
|
|
|
| Third Update: What is the Urologists Role for Theranostics? |
| Thomas Boike, MD, MMM |
| Thomas Boike discusses the urologist’s role in the field of theranostics. Theranostics is a form of diagnostic testing employed for selecting targeted therapy, and, as such, has both diagnostic and therapeutic components. PSMA is a transmembrane protein expressed by the epithelial cells lining the proximal renal tubules, salivary glands, small bowel, as well as the prostate. |
|
|
|
|
|
|
|
|
|
|
|
